Stopatschinskaja, Shanna
Memorial Sloan Kettering Cancer Center · Yonsei University · Asan Medical Center · Massachusetts General Hospital · Bristol-Myers Squibb (United States) · Yonsei Cancer Hospital · University of Colorado Anschutz
2 papers on CoChat
Most cited papers
- Verified
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
Drilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery
Lung Cancer Treatments and MutationsCancer Mechanisms and Therapy
Cited by 504
- Verified
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
Drilon, A., Camidge, D. R., Lin, J. J., Kim, S.-W., Solomon, B. J., Dziadziuszko, R., Besse, B., Goto, K., de Langen, A. J., Wolf, J., et al. (2024) · New England Journal of Medicine
Lung Cancer Treatments and MutationsLung Cancer Research Studies
Cited by 240
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free